



EqStim[®] Immunostimulant



Indications

A USDA approved immunostimulant for adjunctive treatment of equine respiratory disease complex (ERDC).

Do not use in conjunction with glucocorticoids or other immune suppressors. Steroid therapy should be withdrawn at least seven days before initiating this immunostimulant therapy.

Item No.	Description
08890	5 mL bottle – 6/Case
08891	50 mL bottle – 48/Case

Ingredients

Each mL contains:

0.4 mg/ mL non-viable propionibacterium acnes suspended in 12.5% ethanol in saline.

Dosage and Administration

EqStim must be administered by the intravenous (IV) route.

Shake well to obtain uniform suspension

Foals: 1 mL

Older Horses: 1 mL per 250 lbs of body weight

Repeat dosages at day three (or day four) and at day seven, and weekly thereafter as needed.

Caution

May be a rise in temperature, tremors, temporary loss of appetite, or sluggishness a few hours after injection.

Anaphylactoid reactions may occur. In the event of anaphylactoid reaction administer epinephrine.

Warning

The effects of this immunostimulant have not been studied on pregnant animals. Do not use when pregnancy is known or suspected.

For animal use only.
Keep out of reach of children.
Not for human use.

Storage

Store at a temperature between 15°-30° C (56°-86° F) until first used.
Refrigerate after opening.
Do not freeze.



944 Nandino Blvd. Lexington, KY 40511
800-621-8829 (USA/Canada) or 859-254-1224
info@neogen.com | www.neogen.com



EqStim[®]

Immunostimulant



Propionibacterium acnes
(0.4 mg/mL nonviable *P. acnes* suspended in 12.5% ethanol in saline)

Why use EqStim?

EqStim has been demonstrated to be effective in increasing the rate of recovery when used in conjunction with antibiotic or hyperimmune therapy in the treatment of primary and secondary bacterial and viral infections associated with equine respiratory disease complex.

- Proven to provide rapid recovery from bacterial and viral respiratory infections
- Employs no adjuvants - safe for adult horses, ponies, and foals
- Evaluated in mares diagnosed with persistent endometritis. Results of this randomized, double-blinded clinical trial were published in the July 1, 2007 issue of JAVMA¹
- Made in the U.S.A.

¹ Contact Neogen for a complimentary reprint of this article:

Rohrbach, Barton W., VMD, MPH, DACVPM; Peter C. Sheerin, DVM, DACT; Charles K. Cantrell, DVM; Phillip M. Matthews, DVM; John V. Steiner, DVM, DACT; Lewis E. Dodds, DVM. "Effect of adjunctive treatment with intravenously administered *Propionibacterium acnes* on reproductive performance in mares with persistent endometritis." JAVMA July 1, 2007; 231(1): 107-113

